24/7 Market News Snapshot 24 September, 2025 – PepGen Inc. Common Stock (NASDAQ:PEPG)

September 24, 2025

DENVER, Colo., 24 September, 2025 (www.247marketnews.com) – (NASDAQ:PEPG) are discussed in this article.
PepGen Inc. has experienced a significant surge in its stock value, reflecting robust investor interest and confidence. Opening at $1.95, shares have skyrocketed by over 117%, now trading at approximately $4.23, alongside a notable trading volume of 5.76 million shares. This increase has drawn the attention of market analysts, who are monitoring the company’s dynamic growth trajectory as it exploits opportunities within the biotechnology sector.

The recent surge in stock value coincides with the announcement of promising clinical trial results for PGN-EDODM1, PepGen’s innovative therapeutic oligonucleotide aimed at treating myotonic dystrophy type 1 (DM1). In results from the 15 mg/kg cohort of the FREEDOM-DM1 Phase 1 trial, PepGen achieved a mean splicing correction of 53.7%, marking the highest correction reported to date among DM1 patients after a single treatment. This milestone suggests potential for reversing molecular defects associated with the debilitating symptoms of DM1.

Dr. Paul Streck, Executive Vice President of Research and Development at PepGen, underscored the significance of these findings, noting that all patients in the cohort displayed an improvement in splicing correction. Furthermore, Dr. James McArthur, the company’s President and CEO, expressed optimism regarding upcoming data from the FREEDOM2 trial, scheduled to begin in early 2026. The interim safety profile of PGN-EDODM1 has also shown favorability, with only mild or moderate adverse effects reported.

As PepGen advances in its clinical endeavors, the potential to transform treatment options for patients with DM1 grows increasingly promising. With its commitment to pioneering genetic therapies, PepGen is positioned as a significant player in the biotechnology landscape, aiming to address critical healthcare needs in neuromuscular disorders.

Related news for (PEPG)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.